Related Experiment Video

Updated: May 31, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Reducing glucose infusion safely prevents hyperglycemia in post-surgical children

Sascha C A T Verbruggen1, Carlijn T I de Betue, Henk Schierbeek

  • 1Department of Pediatrics, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.

Clinical Nutrition (Edinburgh, Scotland)
|July 2, 2011
PubMed

Insights

Standard glucose infusions cause hyperglycemia in post-surgical children. Lowering glucose infusion safely normalized blood sugar levels, supported by increased endogenous glucose production, without worsening catabolism.

Area of Science:

  • Pediatric Intensive Care
  • Metabolic Research
  • Nutritional Support

Background:

  • Post-surgical children in intensive care face challenges in glucose homeostasis.
  • Amino acid metabolism is crucial for recovery in critically ill pediatric patients.

Purpose of the Study:

  • To compare the effects of low (LG) versus standard (SG) glucose infusion rates on glucose and amino acid metabolism in post-surgical children.
  • To determine optimal glucose infusion strategies for maintaining metabolic stability in pediatric intensive care.

Main Methods:

  • Randomized crossover study in 8 post-surgical infants undergoing craniosynostosis repair.
  • Infusion of stable isotope tracers ([6,6-²H₂]Glucose, [1-¹³C]Leucine, [ring-²H₅]Phenylalanine, [3,3-²H₂]Tyrosine) over 8 hours.
  • Evaluation of glucose kinetics, endogenous glucose production, and whole-body protein balance.

Main Results:

  • Standard glucose infusion (SG) led to hyperglycemia (> 6.1 mmol L⁻¹), whereas low glucose infusion (LG) maintained normoglycemia (5.9 ± 0.6 vs. 7.5 ± 1.7 mmol L⁻¹).
  • Endogenous glucose production was higher during LG and suppressed during SG (p=0.05).
  • Whole-body protein balance remained mildly negative but was unaffected by the reduced glucose infusion rate.

Conclusions:

  • Current standard glucose infusion rates induce hyperglycemia in post-surgical children.
  • A reduced glucose infusion rate is safe, effectively lowers hyperglycemia, and supports normoglycemia through increased endogenous glucose production.
  • Lowering glucose infusion does not worsen the existing mild catabolic state in these patients.
Abstract

More Related Videos

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...